Overall survival from the open-label phase II trial of palbociclib in patients with advanced well-differentiated/dedifferentiated liposarcoma

This study provides the longest prospective OS data for palbociclib in WD/DD LPS. CDK4/6 inhibition remains a relevant treatment option, especially for patients unsuitable for cytotoxic therapy. CDH18 expression was associated with clinical outcomes and represents an exploratory biomarker signal that warrants independent validation in future prospective, biomarker-focused studies.